DrugBank 5.0: a major update to the DrugBank database for 2018
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
DrugBank (www.drugbank.ca) is a web-enabled database containing comprehensive molecular information about drugs, their mechanisms, their interactions and their targets. First described in 2006, DrugBank has continued to evolve over the past 12 years in response to marked improvements to web standards and changing needs for drug research and development. This year's update, DrugBank 5.0, represents the most significant upgrade to the database in more than 10 years. In many cases, existing data content has grown by 100% or more over the last update. For instance, the total number of investigational drugs in the database has grown by almost 300%, the number of drug-drug interactions has grown by nearly 600% and the number of SNP-associated drug effects has grown more than 3000%. Significant improvements have been made to the quantity, quality and consistency of drug indications, drug binding data as well as drug-drug and drug-food interactions. A great deal of brand new data have also been added to DrugBank 5.0. This includes information on the influence of hundreds of drugs on metabolite levels (pharmacometabolomics), gene expression levels (pharmacotranscriptomics) and protein expression levels (pharmacoprotoemics). New data have also been added on the status of hundreds of new drug clinical trials and existing drug repurposing trials. Many other important improvements in the content, interface and performance of the DrugBank website have been made and these should greatly enhance its ease of use, utility and potential applications in many areas of pharmacological research, pharmaceutical science and drug education.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DrugBank primarily contains drug indications extracted from drug labels, while MEDI utilizes public internet sources to drug indications, and is a well utilized resource of drug indications.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, we searched DrugBank84 to identify therapeutic compounds targeting AD-associated proteins. Of the 38 proteins, 15 had reported molecules (Fig. 4D).”
From Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease (2024) · cites this paper as [84]
In the citing paper
“AVPR2 and NPR1 genes play pivotal roles in regulating fluid and electrolyte balance via complementary but distinct pathways. AVPR2 contributes to water retention and urine concentration, whereas NPR1 facilitates vasodilatation, lowers blood pressure and enhances water excretion47.”
From A foundation model for clinician-centered drug repurposing (2024) · cites this paper as [47]
In the citing paper
“In essence, the CC is an alternative representation of the small-molecule knowledge deposited in the public domain and, as such, it is also limited by the availability of experimental data and the coverage of its source databases (e.g., ChEMBL9 or DrugBank10).”
From Bioactivity descriptors for uncharacterized chemical compounds (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892 · cited 1×
“DrugBank 1.0, released in 2006, provided novel (at the time) physico-chemical data on selected FDA-approved drugs and their drug-targets (2).”
BackgroundInfluentialSelf-citationDrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861 · cited 1×
“DrugBank 2.0, released in 2008, added pharmacological, pharmacogenomic and molecular biological data (3).”
BackgroundInfluentialSelf-citationThe new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog)
MacArthur, J., Bowler, E., Cerezo, M., Gil, L., Hall, P., Hastings, E., Junkins, H., McMahon, A., Milano, A., Morales, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1133 · Cited by 2,161 · cited 2×
“org and FDA labels), as well as material collated from sources such as The Human Cytochrome P450 (CYP) Allele Nomenclature Database (12) and the NHGRI-EBI GWAS Catalog (13).”
BackgroundDrugBank 4.0: shedding new light on drug metabolism
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1068 · Cited by 1,993 · cited 1×
“tion, distribution, metabolism, excretion and toxicity) data (5).”
Self-citationDrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,831 · cited 1×
“DrugBank 3.0, released in 2010, added drug–drug and drug–food interactions, drug transporter data as well as pharmacokinetic information (4).”
BackgroundInfluentialSelf-citationClassyFire: automated chemical classification with a comprehensive, computable taxonomy
Djoumbou Feunang, Y., Eisner, R., Knox, C., Chepelev, L., Hastings, J., Owen, G., Fahy, E., Steinbeck, C., Subramanian, S., Bolton, E., et al. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0174-y · Cited by 1,525
Self-citationThe Comparative Toxicogenomics Database: update 2017
Davis, A. P., Grondin, C. J., Johnson, R. J., Sciaky, D., King, B. L., McMorran, R., Wiegers, J., Wiegers, T. C., & Mattingly, C. J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw838 · Cited by 544 · cited 1×
“Additional pharmacoproteomic and pharmacotranscriptomic data were obtained from the CTD (18).”
MethodPredicting drug metabolism: experiment and/or computation?
Kirchmair, J., Göller, A. H., Lang, D., Kunze, J., Testa, B., Wilson, I. D., Glen, R. C., & Schneider, G. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4581 · Cited by 502 · cited 1×
“It has also become much more robust and sophisticated (21).”
BackgroundAllen, F., Pon, A., Wilson, M., Greiner, R., & Wishart, D. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku436 · Cited by 464 · cited 7×
“In particular, CFM-ID (19) and CFM-ID 2.”
BackgroundInfluentialSelf-citationSim, S. C., & Ingelman-Sundberg, M. (2010) · Human Genomics · doi:10.1186/1479-7364-4-4-278 · Cited by 216 · cited 2×
“org and FDA labels), as well as material collated from sources such as The Human Cytochrome P450 (CYP) Allele Nomenclature Database (12) and the NHGRI-EBI GWAS Catalog (13).”
Background
Cited by
Items 401–500 of 1,056
Quantification of fluoroquinolones in wastewaters by liquid chromatography-tandem mass spectrometry
Maia, A. S., Paíga, P., Delerue-Matos, C. M., Castro, P. M. L., & Tiritan, M. E. (2020) · Environmental Pollution · doi:10.1016/j.envpol.2020.113927 · Cited by 106
Computational systems biology in disease modeling and control, review and perspectives
Yue, R., & Dutta, A. (2022) · npj Systems Biology and Applications · doi:10.1038/s41540-022-00247-4 · Cited by 120
“Sensitive to the number of genes and the choices of parameters (i.e., soft threshold). data is parsed from the drug database (e.g., DrugBank database 61 ) by inputting the name of target proteins.”
BackgroundEncinar, J. A., & Menéndez, J. A. (2020) · Viruses · doi:10.3390/v12050525 · Cited by 108
“were downloaded from the DrugBank website as SDS files [52] and converted to MOL2 format using Marvin Suite 6.”
MethodKhan, A., Ali, S. S., Khan, M. T., Saleem, S., Ali, A., Suleman, M., Babar, Z., Shafiq, A., Khan, M., & Wei, D. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1779128 · Cited by 106
“A list of 31 anti-HIV drugs (Table 1) was downloaded from drugbank database (https://www.drugbank.ca/) using their respective accession IDs (Wishart et al., 2018).”
MethodPre-training graph neural networks for link prediction in biomedical networks
Long, Y., Wu, M., Liu, Y., Fang, Y., Kwoh, C. K., Chen, J., Luo, J., & Li, X. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac100 · Cited by 103
Self-citationA review on knowledge graphs for healthcare: Resources, applications, and promises
Cui, H., Lu, J., Xu, R., Wang, S.-Y., Ma, W., Yu, Y., Yu, S., Kan, X., Ling, C., Zhao, L., et al. (2025) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2025.104861 · Cited by 130
Ansar, S., & Vetrivel, U. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.02.012 · Cited by 109
Banegas‐Luna, A. J., Cerón‐Carrasco, J. P., & Pérez‐Sánchez, H. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0076 · Cited by 113
Sun, X., Dong, K., Ma, L., Sutcliffe, R. F. E., He, F., Chen, S., & Feng, J. H. (2019) · Entropy · doi:10.3390/e21010037 · Cited by 116
Repositioning of 8565 Existing Drugs for COVID-19
Gao, K., Nguyen, D. D., Chen, J., Wang, R., & Wei, G. (2020) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.0c01579 · Cited by 104
Born, J., Manica, M., Oskooei, A., Cadow, J., Markert, G., & Martínez, M. R. (2021) · iScience · doi:10.1016/j.isci.2021.102269 · Cited by 119
“For molecules 1 and 2 we obtained Tanimoto coefficients >0.45 for several drugs that are FDA approved for the use against lung cancer, such as vinorelbine, vincristine, vinblastine, irinotecan, topotecan, and alectinib (Wishart et al., 2018).”
BackgroundInfluentialZhang, H., Zhang, Y., Li, Y., Wang, Y., Yan, S., Xu, S., Deng, Z., Yang, X., Xie, H., & Li, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.756550 · Cited by 104
Immune responses in checkpoint myocarditis across heart, blood and tumour
Blum, S. M., Zlotoff, D. A., Smith, N. P., Kernin, I., Ramesh, S., Zubiri, L., Caplin, J., Samanta, N., Martin, S., Wang, M., et al. (2024) · Nature · doi:10.1038/s41586-024-08105-5 · Cited by 114
Xuan, P., Sun, C., Zhang, T., Ye, Y., Shen, T., & Dong, Y. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00459 · Cited by 100
“In this dataset, there are 1923 known DTIs, involving 708 drugs from DrugBank 5.0 (Wishart et al., 2017) and 1,412 targets from HPRD 9.0 (Keshava Prasad et al., 2008).”
BackgroundMethodInfluentialStrodel, B., Olubiyi, O. O., Olagunju, M. O., Keutmann, M., & Loschwitz, J. (2020) · Molecules · doi:10.3390/molecules25143193 · Cited by 102
“Food and Drug Administration (FDA) or other authorities, investigational drugs, natural products, as well as organic compounds that do not necessarily fall into the other mentioned libraries [34,35].”
BackgroundMethodLi, T., Tong, W., Roberts, R. A., Liu, Z., & Thakkar, S. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00374 · Cited by 108
A heterogeneous network embedding framework for predicting similarity-based drug-target interactions
An, Q., & Yu, L. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab275 · Cited by 102
In silico Methods for Identification of Potential Therapeutic Targets
Zhang, X., Wu, F., Yang, N., Zhan, X., Liao, J., Mai, S., & Huang, Z. (2021) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-021-00491-y · Cited by 114
“Reisdorf et al. introduced database resources for identification, prioritization, and validation of disease targets, including emerging integrated bioinformatics platforms, such as Open Targets, and public resources, such as DrugBank and ChEMBL [163].”
BackgroundHolovach, S., Melnykov, K. P., Skreminskiy, A., Herasymchuk, M. V., Tavlui, O., Aloshyn, D., Borysko, P., Rozhenko, A. B., Ryabukhin, S. V., Volochnyuk, D. M., et al. (2022) · Chemistry - A European Journal · doi:10.1002/chem.202200331 · Cited by 102
Chen, Z., Gu, J., Lin, S., Xu, Z., Xu, H., Zhao, J., Feng, P., Tao, Y., Chen, S., & Wang, P. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115719 · Cited by 102
Distributed Plasticity Drives Visual Habituation Learning in Larval Zebrafish
Randlett, O., Haesemeyer, M., Forkin, G., Shoenhard, H., Schier, A. F., Engert, F., & Granato, M. (2019) · Current Biology · doi:10.1016/j.cub.2019.02.039 · Cited by 110
Morris, J. H., Soman, K., Akbas, R. E., Zhou, X., Smith, B., Meng, E. C., Huang, C. C., Cerono, G., Schenk, G., Rizk-Jackson, A., et al. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad080 · Cited by 99
Genetically determined blood pressure, antihypertensive drug classes, and risk of stroke subtypes
Georgakis, M. K., Gill, D., Webb, A. J. S., Εvangelou, Ε., Elliott, P., Sudlow, C. L. M., Dehghan, A., Malik, R., Tzoulaki, I., & Dichgans, M. (2020) · Neurology · doi:10.1212/wnl.0000000000009814 · Cited by 109
A European proposal for quality control and quality assurance of tandem mass spectral libraries
Oberacher, H., Sasse, M., Antignac, J., Guitton, Y., Debrauwer, L., Jamin, E. L., Schulze, T., Krauss, M. K. V., Covaci, A., Caballero‐Casero, N., et al. (2020) · Environmental Sciences Europe · doi:10.1186/s12302-020-00314-9 · Cited by 106
“While both TEDB and DrugBank list MS/MS entries (measured and in silico), this information is not as easily accessible as HMDB and many entries overlap with HMDB Initial benchmarking efforts between the Swiss Federal Institute of Aquatic Science and Technology (Eawag) MassBank collection and the WRTMD were published r…”
BackgroundMethodInfluentialPan, Y. F., Lei, X., & Zhang, Y. (2021) · Medicinal Research Reviews · doi:10.1002/med.21847 · Cited by 105
Zhang, C., Lu, Y., & Zang, T. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04612-2 · Cited by 99
“DeepDDI was proposed [10] to classify the DDIs’ events from DrugBank [24].”
BackgroundCysDB: a human cysteine database based on experimental quantitative chemoproteomics
Boatner, L. M., Palafox, M. F., Schweppe, D. K., & Backus, K. M. (2023) · Cell Chemical Biology · doi:10.1016/j.chembiol.2023.04.004 · Cited by 99
Regulation-aware graph learning for drug repositioning over heterogeneous biological network
Zhao, B.-W., Su, X., Yang, Y., Li, D., Li, G., Hu, P., You, Z.-H., Luo, X., & Hu, L. (2024) · Information Sciences · doi:10.1016/j.ins.2024.121360 · Cited by 110
A wealth of discovery built on the Human Genome Project — by the numbers
Gates, A. J., Gysi, D. M., Kellis, M., & Barabási, A.-L. (2021) · Nature · doi:10.1038/d41586-021-00314-6 · Cited by 98
Evaluation of 3-Dimensionality in Approved and Experimental Drug Space
Prosser, K. E., Stokes, R. W., & Cohen, S. M. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00121 · Cited by 106
Do Drug‐likeness Rules Apply to Oral Prodrugs?
Protti, Í. F., Rodrigues, D. R., Fonseca, S. K., Alves, R. J., de Oliveira, R. B., & Maltarollo, V. G. (2021) · ChemMedChem · doi:10.1002/cmdc.202000805 · Cited by 106
Patient-specific Boolean models of signalling networks guide personalised treatments
Montagud, A., Béal, J., Tobalina, L., Traynard, P., Subramanian, V., Szalai, B., Alföldi, R., Puskás, L. G., Valencia, A., Barillot, E., et al. (2022) · eLife · doi:10.7554/elife.72626 · Cited by 117
“Experimental validation of predicted targets Drugs associated with the proposed targets To identify drugs that could act as potential inhibitors of the genes identified with the Boolean model, we explored the drug- target associations in DrugBank (Wishart et al., 2018) and ChEMBL (Gaulton et al., 2017).”
BackgroundInfluentialThe impact of chemoinformatics on drug discovery in the pharmaceutical industry
Martínez‐Mayorga, K., Madariaga‐Mazón, A., Medina‐Franco, J. L., & Maggiora, G. M. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1696307 · Cited by 103
Interplay between Cellular Metabolism and the DNA Damage Response in Cancer
Moretton, A., & Loizou, J. I. (2020) · Cancers · doi:10.3390/cancers12082051 · Cited by 104
A pharmacophore-guided deep learning approach for bioactive molecular generation
Zhu, H., Zhou, R., Cao, D., Tang, J. P., & Li, M. (2023) · Nature Communications · doi:10.1038/s41467-023-41454-9 · Cited by 120
Walker, V. M., Kehoe, P. G., Martin, R. M., & Davies, N. M. (2018) · doi:10.1101/486878 · Cited by 96
Zhang, Y., Sheng, M., Zhou, R., Wang, Y., Han, G., Zhang, H., Xing, C., & Dong, J. (2020) · Information Processing & Management · doi:10.1016/j.ipm.2020.102324 · Cited by 92
Prasad, K., Khatoon, F., Rashid, S., Ali, N., Alasmari, A. F., Ahmed, M. Z., Alqahtani, A. S., Alqahtani, M. S., & Kumar, V. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.06.228 · Cited by 103
Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases
Ritchie, S. C., Lambert, S. A., Arnold, M., Teo, S. M., Lim, S. I., Šćepanović, P., Marten, J., Zahid, S., Chaffin, M. D., Liu, Y., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00478-5 · Cited by 100
“Nine of these were targets of, or interacted with, 76 compounds in the DrugBank database 36 (Supplementary Table 9).”
BackgroundSelf-citationZhang, P., Wei, Z., Che, C., & Jin, B. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105214 · Cited by 105
Zhu, X. H., Yao, Q., Yang, P., Zhao, D. Y., Yang, R., Bai, H., & Ning, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1031051 · Cited by 102
“The most recent version is DurgBank 5.0, which comprises 2,358 FDA-approved small molecular pharmaceuticals and 4,964 experimental drugs, as well as 7,129 unique drug targets and other drug-associated informantion (Wishart et al., 2018) (Figure 4).”
BackgroundInfluentialWalker, V. M., Kehoe, P. G., Martin, R. M., & Davies, N. M. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyz155 · Cited by 96
“1).(23) We then identified SNPs to instrument each protein target using the GTeX project data (Release V7; dbGaP Accession phs000424.”
MethodRevealing Drug-Target Interactions with Computational Models and Algorithms
Zhou, L., Li, Z., Yang, J., Tian, G., Liu, F., Wen, H., Li, P., Chen, M., Xiang, J., & Peng, L. (2019) · Molecules · doi:10.3390/molecules24091714 · Cited by 102
“DrugBank The DrugBank database [15] (https://www.”
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing
Fang, J., Pieper, A. A., Nussinov, R., Lee, G., Bekris, L., Leverenz, J. B., Cummings, J., & Cheng, F. (2020) · Medicinal Research Reviews · doi:10.1002/med.21709 · Cited by 94
Machine learning approaches for elucidating the biological effects of natural products
Zhang, R., Li, X., Zhang, X., Qin, H., & Xiao, W. (2021) · Natural Product Reports · doi:10.1039/d0np00043d · Cited by 108
Chowdhury, K. H., Chowdhury, M. R., Mahmud, S., Tareq, A. M., Hanif, N. B., Banu, N., Reza, A. S. M. A., Emran, T. B., & Simal‐Gándara, J. (2020) · Biology · doi:10.3390/biology10010002 · Cited by 101
Network bioinformatics analysis provides insight into drug repurposing for COVID-19
Xu, L., Yu, J., Zhang, Z., Ren, J. F., Peluffo, A. E., Zhang, W., Zhao, Y., Wu, J., Yan, K., Cohen, D., et al. (2021) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2021.100090 · Cited by 99
“Having obtained these 78 drugs, we looked for more information, including clinical drug status, drug category, and adverse effect in the Yaozh (https://data.yaozh.com/) and DrugBank [17] databases.”
InfluentialAccurate and interpretable drug-drug interaction prediction enabled by knowledge subgraph learning
Wang, Y., Yang, Z., & Yao, Q. (2024) · Communications Medicine · doi:10.1038/s43856-024-00486-y · Cited by 115
“We preprocess the two benchmark DDI datasets DrugBank 13,32 andTWOSIDES 29,33 followingthesameprocedureadopted by SumGNN 23 .”
Explaining Explanations: Axiomatic Feature Interactions for Deep Networks
Janizek, J. D., Sturmfels, P., & Lee, S. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2002.04138 · Cited by 37
“The targets were compiled using the information available on DrugBank (Wishart et al., 2018).”
MethodZhang, W., Yue, X., Huang, F. F., Liu, R., Chen, Y., & Ruan, C. (2018) · Methods · doi:10.1016/j.ymeth.2018.06.001 · Cited by 94
Pharmacological manipulations of judgement bias: A systematic review and meta-analysis
Neville, V., Nakagawa, S., Zidar, J., Paul, E. S., Lagisz, M., Bateson, M., Løvlie, H., & Mendl, M. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.11.008 · Cited by 102
INTEDE: interactome of drug-metabolizing enzymes
Yin, J., Li, F., Zhou, Y., Mou, M., Lu, Y., Chen, K., Jia, X., Luo, Y., Fu, J., He, X., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa755 · Cited by 97
“Some of these databases (such as DrugBank (22), PDB (23), PharmGKB (24), Protein Atlas (25), TTD (26) and UniProt (27)) provide the enzyme or DME information as part of a broader collection of biological/pharmacological data, and some others (including BRENDA (28), KEGG (29), MetaCyc (30), Reactome (31), SMPDB (32) an…”
BackgroundWei, Y., Li, S., Li, Z., Ziwei, W., & Lin, J. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac192 · Cited by 104
Alturki, N. A., Mashraqi, M. M., Alzamami, A., Alghamdi, Y. S., Alharthi, A., Asiri, S. A., Ahmad, S., & Alshamrani, S. (2022) · Molecules · doi:10.3390/molecules27144391 · Cited by 94
“We have downloaded and prepared the complete experimental library of the Drug Bank database, which gives vast data, and we have prepared them to be ready to dock to the protein complexes [13].”
MethodACID: a free tool for drug repurposing using consensus inverse docking strategy
Wang, F., Wu, F., Li, C., Jia, C., Su, S.-W., Hao, G., & Yang, G. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0394-z · Cited by 100
Self-citationGiebułtowicz, J., Nałęcz‐Jawecki, G., Harnisz, M., Kucharski, D., Korzeniewska, E., & Płaza, G. A. (2020) · Molecules · doi:10.3390/molecules25061470 · Cited by 99
“, the biotransformation ratio of clindamycin is 85% [30].”
BackgroundDrug dosing in the critically ill obese patient—a focus on sedation, analgesia, and delirium
Erstad, B. L., & Barletta, J. F. (2020) · Critical Care · doi:10.1186/s13054-020-03040-z · Cited by 93
Hung, T. N. K., Le, N. Q. K., Le, N. H., Tuấn, L. V., Nguyen, P. T. A., Cao, T., & Kang, J. (2022) · Molecular Informatics · doi:10.1002/minf.202100264 · Cited by 99
Bioactivity descriptors for uncharacterized chemical compounds
Bertoni, M., Duran-Frigola, M., Badia-i-Mompel, P., Pauls, E., Orozco-Ruiz, M., Guitart-Pla, O., Alcalde, V., Diaz, V. M., Berenguer-Llergo, A., Brun-Heath, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24150-4 · Cited by 92
“In essence, the CC is an alternative representation of the small-molecule knowledge deposited in the public domain and, as such, it is also limited by the availability of experimental data and the coverage of its source databases (e.g., ChEMBL 9 or DrugBank 10 ).”
Recent Advances in In Silico Target Fishing
Galati, S., Stefano, M. D., Martinelli, E., Poli, G., & Tuccinardi, T. (2021) · Molecules · doi:10.3390/molecules26175124 · Cited by 99
“This platform is based on the similarity of 2D ligand-receptor interactions obtained from molecules belonging to the DrugBank and proteins contained in the PDB database.”
BackgroundKnowledge-based BERT: a method to extract molecular features like computational chemists
Wu, Z., Jiang, D., Wang, J., Zhang, X., Du, H., Pan, L., Hsieh, C., Cao, D., & Hou, T. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac131 · Cited by 99
Inhibitors of SARS-CoV-2 PLpro
Calleja, D. J., Lessène, G., & Komander, D. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.876212 · Cited by 102
“Still, in the DrugBank database, there are currently over 3,000 clinical trials directed towards repurposing efforts for the treatment of COVID-19.”
BackgroundPasrija, P., Jha, P. K., Upadhyaya, P., Khan, M. S., & Chopra, M. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220701091339 · Cited by 115
Evolution of Influenza Viruses—Drug Resistance, Treatment Options, and Prospects
Smyk, J. M., Szydłowska, N., Szulc, W., & Majewska, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012244 · Cited by 92
“Acknowledgments: All chemical structures were retrieved from DrugBank [107] (go.drugbank.com), (accessed on 25 September 2022).”
BackgroundWang, Z.-Y., Li, M., Li, W., Ouyang, J., Gou, X., & Huang, Y. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154538 · Cited by 99
Gadaleta, D., Lombardo, A., Toma, C., & Benfenati, E. (2018) · Journal of Cheminformatics · doi:10.1186/s13321-018-0315-6 · Cited by 92
Li, T., Wang, C., Xu, Z., & Chakraborty, A. (2020) · Chemosphere · doi:10.1016/j.chemosphere.2020.126765 · Cited by 94
Rodrigues, L. A., Cunha, R. B., Vassilevskaia, T. D., Viveiros, M., & Cunha, C. V. (2022) · Molecules · doi:10.3390/molecules27092723 · Cited by 96
Asada, M., Miwa, M., & Sasaki, Y. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa907 · Cited by 97
Ahmad, S., & Raza, K. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10648-0 · Cited by 93
“The OPLS4 force field was used to minimise the ligands, and the size was restricted to not more than 500 atoms to filter the compounds not fitting into the good drug candidate category [34, 36].”
Spacial Score─A Comprehensive Topological Indicator for Small-Molecule Complexity
Krzyzanowski, A., Pahl, A., Grigalunas, M., & Waldmann, H. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00689 · Cited by 101
Drug–drug interaction prediction: databases, web servers and computational models
Zhao, Y. F., Yin, J., Zhang, L., Zhang, Y., & Chen, X. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad445 · Cited by 110
“Firstly,based on the molecular structure information of drugs recorded in DrugBank [6], a novel molecular representation method named Mol2Context-vec [155] was used to extract the molecular structure features of drugs.”
BackgroundMethodInfluentialParvez, M. S. A., Karim, M. A., Hasan, M., Jaman, J., Karim, Z., Tahsin, T., Hasan, M. N., & Hosen, M. J. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.09.098 · Cited by 108
Ensembling graph attention networks for human microbe–drug association prediction
Long, Y., Wu, M., Liu, Y., Kwoh, C. K., Luo, J., & Li, X. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa891 · Cited by 104
Self-citationDrugMAP: molecular atlas and pharma-information of all drugs
Li, F., Yin, J., Lu, M., Mou, M., Li, Z., Zeng, Z., Tan, Y. C., Wang, S., Chu, X., Dai, H., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac813 · Cited by 93
Lagunin, A. A., Rudik, A. V., Pogodin, P. V., Савосина, П. И., Tarasova, O. A., Dmitriev, A. V., Ivanov, S. M., Biziukova, N. Y., Druzhilovskiy, D. S., Filimonov, D. A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021689 · Cited by 96
“According to Drugbank [23], erlotinib is used in the treatment of nonsmall-cell lung cancer, pancreatic cancer and several other types of cancer.”
BackgroundXAI-Based Clinical Decision Support Systems: A Systematic Review
Kim, S. Y., Kim, D. H., Kim, M. J., Ko, H. J., & Jeong, O. R. (2024) · Applied Sciences · doi:10.3390/app14156638 · Cited by 68
Band Gap Prediction for Large Organic Crystal Structures with Machine Learning
Olsthoorn, B., Geilhufe, R. M., Borysov, S. S., & Balatsky, A. V. (2019) · Advanced Quantum Technologies · doi:10.1002/qute.201900023 · Cited by 95
“, for crystal structures [1–4], electronic structures and materials properties [5–9], enzymes and pharmaceutics [10, 11], or superconductors [12, 13].”
BackgroundDhiman, N., Kingshott, P., Sümer, H., Sharma, C. S., & Rath, S. N. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.02.070 · Cited by 90
Neural network-based approaches for biomedical relation classification: A review
Zhang, Y., Lin, H., Yang, Z., Wang, J., Sun, Y., Xu, B., & Zhao, Z. (2019) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2019.103294 · Cited by 93
The COVID-19 Drug and Gene Set Library
Kuleshov, M. V., Stein, D. J., Clarke, D. J. B., Kropiwnicki, E., Jagodnik, K. M., Bartal, A., Evangelista, J. E., Hom, J., Cheng, M., Bailey, A., et al. (2020) · Patterns · doi:10.1016/j.patter.2020.100090 · Cited by 89
Prajapat, M., Shekhar, N., Sarma, P., Avti, P., Singh, S. K., Kaur, H., Bhattacharyya, A., Kumar, S., Sharma, S., Prakash, A., et al. (2020) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2020.107716 · Cited by 91
A machine learning framework for predicting drug–drug interactions
Mei, S., & Zhang, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-97193-8 · Cited by 95
VARIDT 2.0: structural variability of drug transporter
Fu, T., Li, F., Zhang, Y., Yin, J., Qiu, W., Li, X., Liu, X., Xin, W., Wang, C., Yu, L., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1013 · Cited by 90
Fu, C., Zhang, X., Veri, A. O., Iyer, K. R., Lash, E., Xue, A., Yan, H., Revie, N. M., Wong, C., Lin, Z.-Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26850-3 · Cited by 83
“We paired our fi ndings with drug target databases including DrugBank 29 , Therapeutic Target Database 30 , and PubChem 31 to identify 97 compounds targeting nine of our experimentally con fi rmed essential or predicted essential genes, three of them lacking human orthologs (Supplementary Data 5).”
MethodSu, X., Hu, L., You, Z., Hu, P., Wang, L., & Zhao, B.-W. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab526 · Cited by 89
Borgio, J. F., Alsuwat, H. S., Otaibi, W. M. A., Ibrahim, A. M., Almandil, N. B., Asoom, L. I. A., Salahuddin, M., Kamaraj, B., & AbdulAzeez, S. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.94567 · Cited by 93
“The metabolism of atazanavir might decrease when used together with vapreotide; hence, detailed studies are needed for use of the combination [32].”
BackgroundInfant drug exposure via breast milk
Verstegen, R. H. J., Anderson, P. O., & Ito, S. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14538 · Cited by 89
Pain management in hidradenitis suppurativa and a proposed treatment algorithm
Savage, K. T., Singh, V., Patel, Z. S., Yannuzzi, C. A., McKenzie-Brown, A. M., Lowes, M. A., & Orenstein, L. A. V. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.09.039 · Cited by 92
Khan, F. M., Rasheed, F., Yang, Y., Liu, B., & Zhang, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1385261 · Cited by 99
Enni, M. A., & Maraj, M. A. A. (2022) · American Journal of Advanced Technology and Engineering Solutions · doi:10.63125/j1hbts51 · Cited by 90
Yang, W., Zhang, Z., Yang, Z., Chen, X., Qiao, L., Chen, X., Sun, K., Qu, L., & Yu, B. (2025) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5c01813 · Cited by 87
Deep learning for predicting toxicity of chemicals: a mini review
Tang, W., Chen, J., Wang, Z., Xie, H., & Hong, H. (2018) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2018.1537563 · Cited by 84
“96 There were 6262 chemical – target interaction pairs with known interactions in DrugBank.”
BackgroundSmith, R. D., Clark, J. J., Ahmed, A., Orban, Z. J., Dunbar, J. B., & Carlson, H. A. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.05.024 · Cited by 87
“This information can be used to identify new targets for existing drugs in DrugBank.[28] Ligand similarities are presented in a table on the webpage associated with the structure it is bound.”
BackgroundMethodInfluentialTuwani, R., Wadhwa, S., & Bagler, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-43664-y · Cited by 90
Exploring the chemical space and the bioactivity profile of lactams: a chemoinformatic study
Saldívar‐González, F. I., Lenci, E., Trabocchi, A., & Medina‐Franco, J. L. (2019) · RSC Advances · doi:10.1039/c9ra04841c · Cited by 92
Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
Kocis, P. T., & Vrana, K. E. (2020) · Medical Cannabis and Cannabinoids · doi:10.1159/000507998 · Cited by 87
Predicting drug–drug interactions by graph convolutional network with multi-kernel
Wang, F., Lei, X., Liao, B., & Wu, F. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab511 · Cited by 89
Sequence-based drug-target affinity prediction using weighted graph neural networks
Jiang, M., Wang, S., Zhang, S., Zhou, W., Zhang, Y., & Li, Z. (2022) · BMC Genomics · doi:10.1186/s12864-022-08648-9 · Cited by 79
“The positive samples of the data-set are obtained from two manually managed databases which are DrugBank [30] and matador [31].”
MethodDDI-GCN: Drug-drug interaction prediction via explainable graph convolutional networks
Zhong, Y., Zheng, H., Chen, X., Zhao, Y., Gao, T., Dong, H., Luo, H., & Weng, Z. (2023) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2023.102640 · Cited by 95
“DDI extraction and graph construction Our DDIs dataset is collected from the DrugBank database [20] Version 5.”
Method
Metadata
- Authors
- Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., Pon, A., Knox, C., & Wilson, M.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Wishart, David S
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-11-08
- Volume
- 46
- Issue
- D1
- Pages
- D1074-D1082
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC5753335
- OpenAlex
- W2767891136
- Cited by
- 8,404
- References
- 22
- Citations by year
- 2026: 617 · 2025: 929 · 2024: 1327 · 2023: 1363 · 2022: 1322 · 2021: 1175 · 2020: 957 · 2019: 502 · 2018: 201 · 2017: 5
- FWCI
- 343.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Genome Canada
- Genome Alberta
- Health Canada
- Canadian Institutes of Health Research
- National Human Genome Research Institute
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- DrugBank, drug databases, drug-drug interactions, food-drug interactions, therapeutic target, drug mechanisms, drug indications, pharmacometabolomics, pharmacoproteomics, drug repurposing, clinical trials, investigational drugs
- MeSH terms
- Drug Interactions, User-Computer Interface, Food-Drug Interactions, Polymorphism, Single Nucleotide, Metabolome, Transcriptome, Databases, Pharmaceutical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

